Identify the Optimal TMS Target to Modulate Reward Activity
ConditionNicotine Use Disorder
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-55
SponsorRutgers, The State University of New Jersey
About this trial
Our primary goal will be to identify the optimal prefrontal-cingulate target by systematically measuring the efficacy of various image-based targeting techniques to increase the reward positivity using the 10-Hz TMS protocol in dependent smokers. Our secondary objective will be to measure the targets' effectiveness to increase decision-making capacity using the probabilistic selection task (PST). Our third objective will be to specifically assess whether the TMS targets has a differential impact on state levels of craving relative to baseline (Tobacco Craving Questionnaire \[TCQ\]. We plan to accomplish these three objectives using a randomized, controlled experiment involving 3 sessions.
Eligibility criteria
Qualifiers
Nicotine dependent individuals (according to the Alcohol, Smoking and Substance Involvement Screening Test nicotine dependence score).
Be between the ages of 18 and 55 years old.
Not received substance abuse treatment within the previous 30 days.
Be in stable mental and physical health.
Disqualifiers
Contraindication to MRI (e.g., presence of metal in the skull, orbits or intracranial cavity, claustrophobia).
Contraindication to rTMS (history of neurological disorder or seizure, increased intracranial pressure, brain surgery, or head trauma with loss of consciousness for > 15 minutes, implanted electronic device, metal in the head, or pregnancy).
History of autoimmune, endocrine, viral, or vascular disorder affecting the brain.
History or MRI evidence of neurological disorder that would lead to local or diffuse brain lesions or significant physical impairment.
Trial design
Treatments tested in this trial
- Active 10-Hz TMS to the DLPFC
- Sham TMS-DLPFC
Treatment groups
36 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov